NervGen Pharma Secures FDA Alignment for Registrational Study of NVG-291

summarizeSummary

NervGen Pharma announced successful FDA alignment for its registrational NVG-291 study, a key de-risking event for its lead candidate, despite reporting limited cash reserves in its Q1 2026 financial results.

check_boxKey Events

• FDA Alignment for Registrational Study

  NervGen completed a successful End-of-Phase 2 meeting with the FDA, securing alignment on the study parameters for RESTORE, a registrational study of NVG-291 in chronic tetraplegia. Site activation is underway, and study initiation is on track for mid-2026.

• Q1 2026 Financial Results

  The company reported $16.6 million in cash and investments as of March 31, 2026, with a net loss of $1.7 million for the quarter. This follows previous warnings about limited cash reserves and a 'going concern' opinion from its auditor.

• Upcoming Clinical Data

  Results from independent, blinded biomechanical gait analyses of the Phase 1b/2a CONNECT SCI study are anticipated in Q2 2026, designed to objectively differentiate genuine neural recovery from compensatory movement.

auto_awesomeAnalysis

NervGen Pharma has achieved a critical milestone by securing FDA alignment on the study parameters for its registrational RESTORE study of NVG-291 in chronic tetraplegia. This de-risks the clinical development path for their lead candidate, which is crucial for a clinical-stage biopharmaceutical company. While the company reported $16.6 million in cash and investments as of Q1 2026, following previous 'going concern' warnings and explicit statements about limited cash runway, this positive clinical progress provides a significant long-term catalyst. The initiation of a registrational study is a major step towards potential market approval and could attract future funding or partnerships.